This is a working overview of TH9507, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
==== Units ==== Due to the variety of natural and synthetic compounds with vitamin E activity, there has historically been many different units that attempt to produce a measure of "vitamin E activity" using a weighted sum. The international unit measurement was used by the United States in 1968–2016. 1 IU is the biological equivalent of about 0.667 mg d (RRR)-alpha-tocopherol (2/3 mg exactly), or of 0.90 mg of dl-alpha-tocopherol (or of 1.0 mg of dl-alpha-tocopherol acetate), corresponding to the then-measured relative potency of stereoisomers. In May 2016, the measurements were revised, such that 1 mg "as alpha-tocopherol" of Vitamin E is 1 mg of d-alpha-tocopherol or 2 mg of dl-alpha-tocopherol. The change was originally started in 2000, when forms of vitamin E other than alpha-tocopherol were dropped from dietary calculations by the IOM. The UL amount disregards any conversion. The EFSA has never used an IU unit, and their measurement only considers RRR-alpha-tocopherol.
Major (Gurkha Commissioned Officer) Lilbahadur Gurung (513800), Queen's Gurkha Signals. Major Lester Andrew Holley (505640), The Royal Gurkha Rifles. Major Anthony Lovell Jackson (509141), Royal Regiment of Artillery. Acting Major John Frederick Kemp (486467), Kent Army Cadet Force, Territorial Army. 24011748 Warrant Officer Class 2 Christopher Keogh, Royal Regiment of Artillery. 24256499 Corporal of Horse Ian Kirkpatrick, The Life Guards. Major Robert Scott Lawther (520854), The Royal Irish Regiment. Major Philip John Leighton (509537), The Green Howards. Major Allan Charles LeQuelenec (520025), Royal Army Medical Corps. Major Richard Allen Licence (530853), Royal Corps of Signals. Major Simon Jonathan Alun Lloyd (499742), Royal Regiment of Artillery. 24435856 Warrant Officer Class 2 John MacKinnon, Corps of Royal Engineers. Lieutenant Colonel Donald Anderson MacLean (Retired). Acting Lieutenant Colonel Peter David Marsden (473626), Monkton Combe School Combined Cadet Force, Territorial Army. 24335098 Warrant Officer Class 1 Terence George Morrissey, Adjutant General's Corps (SPS). Lieutenant Stuart Joseph Nye (546430), The Princess of Wales's Royal Regiment. 24853206 Lance Corporal (Acting Corporal) Derrick Anthony O'Connor, Corps of Royal Engineers. 24413672 Colour Sergeant Stuart Owen Oliver, The Royal Regiment of Fusiliers. Lieutenant (Acting Captain) Nigel Derek Partington (546198), Royal Army Medical Corps. Captain (Acting Major) Brian William Pitchforth (537833), The Parachute Regiment. 24256052 Warrant Officer Class 1 Joseph Thomas Preece, The Light Dragoons.
=== Pre-cigarette === Texts on the harmful effects of smoking tobacco were recorded in the Timbuktu manuscripts. James I wrote a book that denounced tobacco smoking as: "loathsome to the eye, hateful to the nose, harmful to the brain, dangerous to the lungs". Pipe smoking gradually became generally accepted as a cause of mouth cancers following work done in the 1700s. "An association between a variety of cancers and tobacco use was repeatedly observed from the late 1800s into the early 1920s." Gideon Lincecum, an American naturalist and practitioner of botanical medicine, wrote in the early 19th century on tobacco: "This poisonous plant has been used a great deal as a medicine by the old school faculty, and thousands have been slain by it. ... It is a very dangerous article, and use it as you will, it always diminishes the vital energies in exact proportion to the quantity used – it may be slowly, but it is very sure." The 1880s invention of automated cigarette-making machinery in the American South made it possible to mass-produce cigarettes at low cost, and smoking became common. This led to a backlash and a tobacco prohibition movement, which challenged tobacco use as harmful and brought about some bans on tobacco sale and use. In 1912, American Dr. Isaac Adler was the first to strongly suggest that lung cancer is related to smoking. In 1924, economist Irving Fisher wrote an anti-smoking article for Reader's Digest which said "tobacco lowers the whole tone of the body and decreases its vital power and resistance ...
Pyruvate is plentiful in muscle due to extensive glycolysis. Amino groups in skeletal muscles are transferred to a product of glycolysis, pyruvate, forming alanine. This transamination reaction is catalyzed by alanine aminotransferase. Alanine is then transported to the liver, where it is converted back into pyruvate (used for gluconeogenesis) by transferring its amino group to α-ketoglutarate, forming glutamate. Simultaneously, glucose is being transported from the liver (where it's more abundant due to gluconeogenesis) to the muscle, where it is consumed. This is the glucose-alanine cycle.
Between 1676 and 1689, Gottfried Leibniz first attempted a mathematical formulation of the kind of energy that is associated with motion (kinetic energy). Using Huygens's work on collision, Leibniz noticed that in many mechanical systems (of several masses mi, each with velocity vi),
Sources: en.wikipedia.org
== External links == Overview at colostate.edu Nosek, Thomas M. "Section 6/6ch2/s6ch2_27". Essentials of Human Physiology. Archived from the original on 2016-03-24. Enteroglucagon at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
=== Understanding before science === The value of eating certain foods to maintain health was recognized long before vitamins were identified in modern science. The ancient Egyptians knew that feeding liver to a person may help with night blindness, an illness now known to be caused by a vitamin A deficiency. The advance of ocean voyages during the Age of Discovery resulted in prolonged periods without access to fresh fruits and vegetables, and made illnesses from vitamin deficiency common among ships' crews.
== Personal life == Austin played college football at the University of North Texas. Austin married his high school girlfriend Kathryn Burrhus on November 24, 1990. However, he later pursued a relationship with English wrestling manager Jeanie Clarke, with whom he was working. His marriage to Burrhus was annulled on August 7, 1992, while he was in Japan and he married Clarke on December 18, on his 28th birthday. They had two daughters before divorcing in 1999. Austin also adopted Clarke's daughter from a previous relationship with Chris Adams. Austin's adoptive daughter was married to fellow professional wrestler Adam Bryniarski until his death in 2022. In 1998, Austin was the recipient of Hamilton, Ontario's "Key to the City", he is one of two people to ever be bestowed the honor, the other being the basketball player Shai Gilgeous-Alexander. That same year on September 1, the city of Lowell, Massachusetts declared that date Stone Cold day along with naming a street after him for the day. The date March 16 is commonly associated with Austin due to the date matching up with his wrestling catchphrase "Austin 3:16". On September 13, 2000, Austin married wrestling manager Debra Marshall. On June 15, 2002, Marshall called the police to the couple's home. She told officers that Austin had hit her and then stormed out of the house before police arrived. An arrest warrant was issued by the Bexar County district attorney's office on August 12 and Austin turned himself in the following day, at which point he was charged with domestic abuse.
Pottery – many indigenous American cultures and peoples independently invented and then refined pottery in the Americas into fine works of art, as well for utilitarian usage. The Moche and Maya were some of the best potters from the ancient Americas, and their work still inspires awe amongst us for the level of artistry, creativity, and sophistication, which such highly prized works of arts involved. The Navajo are also very skilled developers of pottery and their works in the present time are highly detailed and much prized. Many other indigenous American cultures also developed their own pottery styles during the pre-Columbian time periods and continued to refine their artwork into the modern era. Pumpkins – indigenous Americans were the first to domesticate and grow pumpkins. Puna ibis - the Puna ibis was domesticated by the Uru people. Puquios Pyramids – advanced civilizations in Mexico, such as the Toltecs, Olmecs, Zapotecs, Aztecs, Mayans, Mixtecs, developed their own myriad styles of pyramids, usually step pyramid, which served for ceremonial/religious and administrative functions. In Mesoamerica, the largest pyramid in the world—The Great Pyramid of Cholula—began to be constructed by the inhabitants of Cholula in the 3rd century BCE. In the Andean regions, the Moches, and some ancient Peruvians also constructed gigantic pyramids as well without any influence from Old World civilizations.
Sources: en.wikipedia.org
==== Deficit in consolidation of memory traces ==== α-CaMKII heterozygous mice express half the normal protein level as the wild-type level. These mice showed normal memory storage in the hippocampus, but deficits in consolidation of memory in the cortex.
Following a 15-month ATP-commissioned investigation conducted by The Lake Forest Group (a third-party consultant working with the ATP's outside legal counsel, Smith Hulsey & Busey), the ATP announced in late January 2023 that they would not punish Zverev due to insufficient evidence to substantiate the allegations.
=== Armenia === On April 24, 1999, the founding meeting of the International Armenian-Cossack Friendship and Cooperation Association was held in Yerevan. There is a Separate Cossack District of the Great Don Army operating in Armenia. The organization was established by the decision of the Council of Atamans on December 15, 2015. It is a partner of the Ministry of Defense of Armenia.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.